The Aethlon Hemopurifier selectively targets the removal of infectious viruses and immunosuppressive proteins from the entire circulatory system.

Aethlon, based on studies conducted by government and non-government research organisations, believes that the Hemopurifier represents the advanced and the true broad-spectrum countermeasure against viral threats to be weaponised against civilian and military populations.

Aethlon chairman and CEO Jim Joyce said that revamped government policies expand the opportunity for their Hemopurifier in the US and improve their potential access to non-dilutive capital resources, which are not capped by the public market value of their organisation.

“We plan to update an investigational device exemption (IDE) already submitted to the FDA, which if approved, would allow us to collect further clinical data that potentially could contribute to other infectious disease and cancer studies we hope to initiate in the US,” Joyce said.